CRISPR Therapeutics Reaches Milestone in Sickle Cell Disease Treatment
CRISPR Therapeutics has achieved a significant milestone by successfully treating a sickle cell disease patient using gene-edited stem cells, addressing the condition at its genetic root.
Published on April 10, 2025
CRISPR Therapeutics has made a breakthrough by successfully treating a patient with sickle cell disease through an innovative gene-editing approach. By modifying the patient’s stem cells to produce healthy hemoglobin, the treatment addresses the root cause of the disease and marks an important milestone in genetic medicine as reported in 2023.
Additional developments in the field show a growing global momentum towards gene therapies for blood disorders. Recent regulatory approvals, including the U.S. FDA’s nod for CASGEVY™ (exagamglogene autotemcel) in December 2023 and conditional marketing authorization from the European Commission in February 2024, underline the expanding commitment to innovative treatments for sickle cell disease. Complementary efforts in the UK, as highlighted by Reuters, further emphasize the coordinated push to make these therapies available to patients in need in the coming years.